BRPF1

Across TCGA pan-cancer cohorts, BRPF1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of BRPF1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where BRPF1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BRPF1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, COAD, and STAD are the cancer types where BRPF1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRPF1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.920	<.001	9	view →
COAD	Female	All	+0.537	<.001	9	view →
STAD	Male	II,III,IV	+0.973	<.001	8	view →
BLCA	Male	All	+0.479	.013	6	view →
CHOL	Male	All	+1.699	<.001	5	view →
THCA	All	All	−0.253	.004	5	view →
HNSC	Male	All	+0.312	.025	2	view →
KICH	All	All	−0.439	.011	1	view →
KIRP	Female	All	+0.418	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

BRPF1–LIHC

Open the LIHC breakdown →